NASDAQ: LTRN - Lantern Pharma Inc.

Rentabilität für sechs Monate: +0.5714%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Lantern Pharma Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

weitere details
In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2020-06-11
ISIN US51654W1018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lanternpharma.com
Цена ао 3.65
Preisänderung pro Tag: -0.2833% (3.53)
Preisänderung pro Woche: +36.43% (2.58)
Preisänderung pro Monat: -7.37% (3.8)
Preisänderung über 3 Monate: +0.8596% (3.49)
Preisänderung über sechs Monate: +0.5714% (3.5)
Preisänderung pro Jahr: -41.04% (5.97)
Preisänderung über 3 Jahre: -47.7% (6.73)
Preisänderung seit Jahresbeginn: +9.66% (3.21)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 1.08 9
P/E 0 0
EV/EBITDA -1.27 0
Gesamt: 3.63

Effizienz

Name Bedeutung Grad
ROA, % -36.57 0
ROE, % -39.02 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0132 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 557.78 10
Rentabilität EPS, % 276.99 10
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 365334 3.4
NewEdge Advisors, LLC 165972 1.55
Geode Capital Management, LLC 95036 0.88
CM Management, LLC 80000 0.74
Carlson Capital. L.P. 60000 0.56
Commonwealth Equity Services, LLC 58848 0.55
Renaissance Technologies, LLC 43800 0.41
Redmond Asset Management, LLC 40662 0.38
Horizon Kinetics Asset Management LLC 28791 0.27
State Street Corporation 27752 0.26



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Panna Sharma PH.D. President, CEO & Director 684.38k 1971 (54 Jahr)
Mr. David R. Margrave CFO & Secretary 442.68k 1961 (64 Jahr)
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 283.24k 1955 (70 Jahre)
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator N/A
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor N/A
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations N/A
Dr. Marc C. Chamberlain M.D. Chief Medical Officer of Starlight Therapeutics

Adresse: United States, Dallas. TX, 1920 McKinney Avenue - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.lanternpharma.com